Works by Rehman, Muhammad I.

Results: 7

The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.

Published in:

Therapeutic Advances in Gastroenterology, 2019, v. 12, p. N.PAG, doi. 10.1177/1756284819852535

By:

McClellan, Joseph E.;
Conlon, Hugh D.;
Bolt, Michael W.;
Kalfayan, Vatche;
Palaparthy, Rameshraja;
Rehman, Muhammad I.;
Kirchhoff, Carol F.

Publication type:

Article

The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.

Published in:

Therapeutic Advances in Gastroenterology, 2019, v. 12, p. N.PAG, doi. 10.1177/1756284819852535

By:

McClellan, Joseph E.;
Conlon, Hugh D.;
Bolt, Michael W.;
Kalfayan, Vatche;
Palaparthy, Rameshraja;
Rehman, Muhammad I.;
Kirchhoff, Carol F.

Publication type:

Article

A comparative study of PF‐06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.

Published in:

International Journal of Rheumatic Diseases, 2020, v. 23, n. 7, p. 876, doi. 10.1111/1756-185X.13846

By:

Kameda, Hideto;
Uechi, Eishi;
Atsumi, Tatsuya;
Abud‐Mendoza, Carlos;
Kamei, Kazumasa;
Matsumoto, Tsugumi;
Ponce de Leon, Dario;
Rehman, Muhammad I.;
Zhang, Min;
Radominski, Sebastiao C.

Publication type:

Article

Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis.

Published in:

Expert Opinion on Biological Therapy, 2019, v. 19, n. 10, p. 1065, doi. 10.1080/14712598.2019.1635583

By:

Palaparthy, Rameshraja;
Rehman, Muhammad I.;
von Richter, Oliver;
Yin, Donghua

Publication type:

Article

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial

Published in:

BioDrugs, 2020, v. 34, n. 2, p. 197, doi. 10.1007/s40259-019-00403-z

By:

Cohen, Stanley B.;
Radominski, Sebastiao C.;
Kameda, Hideto;
Kivitz, Alan J.;
Tee, Michael;
Cronenberger, Carol;
Zhang, Min;
Hackley, Sarah;
Rehman, Muhammad I.;
von Richter, Oliver;
Alten, Rieke

Publication type:

Article

A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).

Published in:

Expert Review of Clinical Immunology, 2018, v. 14, n. 4, p. 329, doi. 10.1080/1744666X.2018.1446829

By:

Palaparthy, Ramesh;
Udata, Chandrasekhar;
Hua, Steven Y.;
Yin, Donghua;
Cai, Chun-Hua;
Salts, Stephanie;
Rehman, Muhammad I.;
McClellan, Joseph;
Meng, Xu

Publication type:

Article

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.

Published in:

Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1646-4

By:

Cohen, Stanley B.;
Alten, Rieke;
Kameda, Hideto;
Hala, Tomas;
Radominski, Sebastiao C.;
Rehman, Muhammad I.;
Palaparthy, Ramesh;
Schumacher, Karl;
Schmitt, Susanne;
Hua, Steven Y.;
Ianos, Claudia;
Lea Sewell, K.

Publication type:

Article